EDAP Receives FDA Clearance of its Ablatherm-Fusion Device

EDAP TMS received FDA approval of its Ablatherm-Fusion device that enables more precise targeting of diagnosed areas within the prostate.

The device combines MRI, 3D biopsy maps and ultrasound images to facilitate the targeting of areas to be ablated.

These new features improve Ablatherm's ability to perform efficient focal ablation of prostate tissue.